The future of the medical industry will be shaped by a series of disruptive themes, with genomics being one of the themes that will have a significant impact on medical businesses.
Genomics refers to the study of a complete set of DNA within an organism. This includes researching their molecular components, gene structures and functions, and developing technologies to map and modify DNA sequences. What began as a global scientific endeavor to map the human genome in the 1990s has also created an entirely new commercial market, in which companies are using genomics technologies to provide personal genomics testing services directly to consumers. This has allowed consumers to gain unprecedented insight into their health, wellness, and even family ancestry, all from a genomic perspective.
Players in the genomics market range from small private companies specializing in specific value chains to large corporations that dominate several sectors. Three stages of the genomics value chain can be considered: manufacturers of technologies that allow the analysis of huge amounts of genetic data, providers of direct-to-consumer genetic testing services, and providers of genetic reanalysis services. given by third parties.
However, not all companies are equal when it comes to their capabilities and investments in the key themes that matter most to their industry. Understanding how companies are positioned and ranked in the most important themes can be a key indicator of their future earnings potential and relative competitive position.
According to GlobalData’s topical research report, Genomics in Medical Devices, the top adopters are: Illumina, InVitae, 23&Me, Ancestry.com, and Veritas Genetics.
Overview of a leading company
Illumina provides genomic sequencing and array solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio includes sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and matrices and reagents. It offers human whole genome sequencing; microgrid services; and instrument services, training and consulting. Illumina offers its services to pharmaceutical companies, genome research centers, academic institutions, biotechnology companies and clinical research organizations. The Company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East and Africa. Illumina is headquartered in San Diego, California, USA.
Illumina is the leading original equipment manufacturer in the direct-to-consumer genetic testing market. The company supplies the vast majority of SNP-BeadArray chips to major market leaders such as 23andMe, MyHeritage and Ancestry.com. Moreover, it is a major player in the market for next-generation sequencing reagents.
To better understand the key themes and technologies disrupting the industry, access GlobalData’s latest topical research report on Genomics in Medical Devices.
- Zimmer Biomet
- Scientific Boston
- Becton Dickinson
- Nihon Kohten
- Intuitive surgery
- Blacksmith and nephew
- Edwards life sciences
#Leading #medical #companies #subject #genomics